Obinutuzumab - Roche

Drug Profile

Obinutuzumab - Roche

Alternative Names: 949142-50-1; Afutuzumab; GA-101; Gazyva; Gazyvaro; R-7159; RG 7195; RG-7159; RO-5072759

Latest Information Update: 05 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GLYCART Biotechnology
  • Developer Biogen Idec; Chugai Pharmaceutical; Dana-Farber Cancer Institute; Genentech; Nippon Shinyaku; OHSU Knight Cancer Institute; Roche
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD20 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Follicular lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Phase III Diffuse large B cell lymphoma
  • Phase II CNS cancer; Graft-versus-host disease; Lupus nephritis; Mantle-cell lymphoma
  • Discontinued Primary biliary cirrhosis; Renal failure

Most Recent Events

  • 22 Dec 2017 Roche plans a post-marketing surveillance trial for Chronic Lymphocytic Leukemia and Follicular Lymphoma in South Korea , (NCT03374137)
  • 15 Dec 2017 Launched for Chronic lymphocytic leukaemia in South Korea (IV) before December 2017 (NCT03374137)
  • 15 Dec 2017 Launched for Follicular lymphoma in South Korea (IV) before December 2017 (NCT03374137)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top